

<b>NCT ID</b>	NCT06039384
<b>Title</b>	A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-09-15
<b>Location</b>	California, United States Colorado, United States Michigan, United States Texas, United States Virginia, United States Italy Spain United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Terminated
<b>Drugs</b>	Adagrasib, INCB099280
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05652894
<b>Title</b>	A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
<b>Phase</b>	Phase 3
<b>Date Added</b>	2022-12-15
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	HX008, Investigator's Choice Chemotherapy
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT03970382
<b>Title</b>	A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-05-31
<b>Location</b>	California, United States Illinois, United States New York, United States Tennessee, United States Washington, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Suspended
<b>Drugs</b>	IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03013218
<b>Title</b>	A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2017-01-06

<b>Location</b>	Colorado, United States
	Connecticut, United States
	Massachusetts, United States
	Michigan, United States
	Washington, United States
	Korea, Republic of
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Completed
<b>Drugs</b>	5-FU + Cisplatin, Evorpacept (ALX148), Pembrolizumab, Ramucirumab + Paclitaxel, Rituximab, Trastuzumab
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT04607421
<b>Title</b>	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
<b>Phase</b>	Phase 3
<b>Date Added</b>	2020-10-29

<b>Location</b>	Arizona, United States
	California, United States
	Florida, United States
	Illinois, United States
	Louisiana, United States
	Minnesota, United States
	Missouri, United States
	Nebraska, United States
	New Jersey, United States
	New York, United States
	Ohio, United States
	Oklahoma, United States
	Oregon, United States
	Pennsylvania, United States
	Tennessee, United States
	Texas, United States
	Virginia, United States
	Washington, United States
	Wisconsin, United States
	Argentina
	Australia
	Belgium
	Brazil
	Bulgaria
	Canada
	China
	Czechia
	Denmark
	Finland
	Germany
	India
	Italy
	Japan
	Korea, Republic of
	Mexico
	Netherlands
	New Zealand
	Norway
	Poland
	Russian Federation
	Slovakia
	South Africa
	Spain
	Sweden
	Taiwan
	Ukraine
	United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05217446
<b>Title</b>	A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK )
<b>Phase</b>	Phase 2
<b>Date Added</b>	2022-02-01

<b>Location</b>	Arizona, United States California, United States Florida, United States Tennessee, United States Texas, United States Australia Belgium Canada Czechia Denmark France Germany Italy Netherlands Norway Poland Slovakia Spain United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	encorafenib, Braftovi, Erbitux, Keytruda
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT05726864
<b>Title</b>	A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-02-14
<b>Location</b>	Arizona, United States California, United States Colorado, United States Florida, United States Georgia, United States Iowa, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	ELI-002 7P
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT04104776
<b>Title</b>	A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-09-26

<b>Location</b>	Georgia, United States Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States Washington, United States France Italy Korea, Republic of Poland Spain United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	CPI-0209, CPI-0209
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05759728
<b>Title</b>	A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-03-08
<b>Location</b>	Australia
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03783403
<b>Title</b>	A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-12-21
<b>Location</b>	Alabama, United States Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada France Italy Korea, Republic of Spain United Kingdom

Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	CC-95251, cetuximab, Rituximab
Tags	MSS/ MMRp